A Study of Injection HB0025 in Patients With Advanced Solid Tumors

Summary

This is a multicenter, open-label, dose escalation and expansion study. During the study, subjects will be evaluated for safety, toxicity, tolerability, PK/PD, immunogenicity, biomarkers, and antitumor activity of HB0025. The phase I study will enroll up to 154 subjects with advanced solid tumors who have progressed on or after standard of care therapy and for whom there is no further treatment available that in the judgement of the patient's physician would be beneficial. One cycle is defined as 28 days.

Timeline

Start

2021-03-10

Primary completion

2024-02-02

Completion

2024-05-23

Drugs

Indications